Ken Fisher
BCRX icon

Ken Fisher’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ken Fisher’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26M Buy
2,733,253
+265,686
+11% +$2.06M 0.01% 302
2025
Q4 		$19.2M Sell
2,467,567
-165,129
-6% -$1.19M 0.01% 327
2025
Q3 		$20M Sell
2,632,696
-149,793
-5% -$1.25M 0.01% 322
2025
Q2 		$24.9M Sell
2,782,489
-269,648
-9% -$2.51M 0.01% 291
2025
Q1 		$22.9M Sell
3,052,137
-130,480
-4% -$1.05M 0.01% 309
2024
Q4 		$23.9M Sell
3,182,617
-155,445
-5% -$1.18M 0.01% 326
2024
Q3 		$25.4M Buy
3,338,062
+481,359
+17% +$3.66M 0.01% 311
2024
Q2 		$17.7M Sell
2,856,703
-27,916
-1% -$154K 0.01% 353
2024
Q1 		$14.7M Buy
2,884,619
+50
+0% +$281 0.01% 370
2023
Q4 		$17.3M Sell
2,884,569
-300,630
-9% -$1.74M 0.01% 346
2023
Q3 		$22.6M Sell
3,185,199
-1,139,354
-26% -$8.19M 0.01% 335
2023
Q2 		$30.4M Buy
4,324,553
+31,157
+0.7% +$250K 0.02% 318
2023
Q1 		$35.8M Sell
4,293,396
-137,718
-3% -$1.33M 0.02% 288
2022
Q4 		$50.9M Sell
4,431,114
-732,731
-14% -$9.14M 0.03% 240
2022
Q3 		$65.1M Sell
5,163,845
-52,984
-1% -$682K 0.05% 213
2022
Q2 		$55.2M Buy
5,216,829
+1,230,006
+31% +$12.7M 0.04% 213
2022
Q1 		$64.8M Sell
3,986,823
-110,229
-3% -$1.77M 0.04% 215
2021
Q4 		$56.7M Buy
4,097,052
+1,091,430
+36% +$14.4M 0.03% 233
2021
Q3 		$43.2M Buy
3,005,622
+994,391
+49% +$15.7M 0.03% 247
2021
Q2 		$31.8M Buy
+2,011,231
New +$27.3M 0.02% 276

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Ken Fisher's BCRX Position: Q1 2026 in Review

Ken Fisher increased its BioCryst Pharmaceuticals (BCRX) stake by 11% in Q1 2026, buying an estimated $2.06M and bringing the position to 2,733,253 shares worth $26M. The position accounts for 0.01% of the portfolio, ranked #302.

Ken Fisher first reported a position in BCRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $65.1M in Q3 2022. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Ken Fisher held 2,733,253 shares of BioCryst Pharmaceuticals worth $26M as of Q1 2026.
  • Ken Fisher bought 265,686 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $2.06M.
  • BioCryst Pharmaceuticals made up 0.01% of Ken Fisher's portfolio in Q1 2026, its #302 holding.
  • Ken Fisher first reported a position in BioCryst Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Ken Fisher's BioCryst Pharmaceuticals position peaked at $65.1M in Q3 2022.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.